GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Senzime AB (OSTO:SEZI) » Definitions » Institutional Ownership

Senzime AB (OSTO:SEZI) Institutional Ownership : 18.27% (As of Jun. 10, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Senzime AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Senzime AB's institutional ownership is 18.27%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Senzime AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Senzime AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Senzime AB Institutional Ownership Historical Data

The historical data trend for Senzime AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senzime AB Institutional Ownership Chart

Senzime AB Historical Data

The historical data trend for Senzime AB can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 16.35 16.14 17.55 17.96 18.14 18.26 18.26 18.27 18.26 18.27

Senzime AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Senzime AB (OSTO:SEZI) Business Description

Traded in Other Exchanges
Address
Ulls vag 41, Uppsala, SWE, 756 51
Senzime AB, a medical technology company, develops, manufactures, and markets patient monitoring systems for monitoring patients. Its solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease healthcare costs. Its product includes TetraGraph and TetraSens, ExSpiron, TetraSens Pediatric, and TetraConnect. Its geographical segments include Sweden, the United States, Europe/Oceania, and Asia.

Senzime AB (OSTO:SEZI) Headlines

No Headlines